1257 related articles for article (PubMed ID: 33155660)
21. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
22. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
24. CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.
Yang Y; Hu S; Liu J; Cui Y; Fan Y; Lv T; Liu L; Li J; He Q; Han W; Yu W; Sun Y; Jin J
Sci Rep; 2017 Feb; 7():42893. PubMed ID: 28216616
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects.
Gruszka A; Pawlikowski M; Kunert-Radek J
Neuro Endocrinol Lett; 2001 Oct; 22(5):343-8. PubMed ID: 11600876
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
28. CEBPD suppresses prolactin expression and prolactinoma cell proliferation.
Tong Y; Zhou J; Mizutani J; Fukuoka H; Ren SG; Gutierrez-Hartmann A; Koeffler HP; Melmed S
Mol Endocrinol; 2011 Nov; 25(11):1880-91. PubMed ID: 21980073
[TBL] [Abstract][Full Text] [Related]
29. Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay.
Kojima Y; Arita J; Kuwana N; Kimura F
Endocr J; 1995 Jun; 42(3):355-60. PubMed ID: 7670564
[TBL] [Abstract][Full Text] [Related]
30. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
[TBL] [Abstract][Full Text] [Related]
31. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
Keller A; Wingelhofer B; Peter B; Bauer K; Berger D; Gamperl S; Reifinger M; Cerny-Reiterer S; Moriggl R; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2018 Mar; 16(1):55-68. PubMed ID: 28397975
[TBL] [Abstract][Full Text] [Related]
32. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
33. Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
Missale C; Boroni F; Losa M; Giovanelli M; Zanellato A; Dal Toso R; Balsari A; Spano P
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):7961-5. PubMed ID: 8367448
[TBL] [Abstract][Full Text] [Related]
34. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
[TBL] [Abstract][Full Text] [Related]
35. Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.
Mapes J; Anandan L; Li Q; Neff A; Clevenger CV; Bagchi IC; Bagchi MK
J Biol Chem; 2018 Feb; 293(8):2850-2864. PubMed ID: 29321207
[TBL] [Abstract][Full Text] [Related]
36. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
37. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
38. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
Johnston AN; Bu W; Hein S; Garcia S; Camacho L; Xue L; Qin L; Nagi C; Hilsenbeck SG; Kapali J; Podsypanina K; Nangia J; Li Y
Breast Cancer Res; 2018 May; 20(1):42. PubMed ID: 29778097
[TBL] [Abstract][Full Text] [Related]
39. Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects.
Duan JF; Zhang QJ; Zhu J; Lu JH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23734. PubMed ID: 38764151
[TBL] [Abstract][Full Text] [Related]
40. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]